Tipranavir
As of the edition of 20 October 2026, Tipranavir is a small molecule: marketed, first approved in 2005 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2005
- Kind
- Small molecule
- Brand name
- Aptivus
- First approved
- 22 June 2005 (US)
- Approvals on record
- 4 in 2 regions
- Holder of the most recent approval
- Boehringer Ingelheim
- Registered trials
- 52, 7 stopped early
- Disease areas
- Immune system; Infections; Urinary and reproductive; Digestive system; Heart and blood vessels; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 5 | 0 | 1 |
| Phase 1 | 25 | 24 | 0 | 1 |
| Phase 2 | 8 | 6 | 0 | 2 |
| Phase 3 | 8 | 5 | 0 | 3 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 52 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Originator and Lead sponsor of trials | 1999 to now |